EGFR and non-small cell lung carcinoma: The combination of platinum-based therapy and pemetrexed has been widely used in patients with centrally confirmed EGFR T790M-positive advanced NSCLC demonstrating progressive disease (PD) after first-line (1L) EGFR-TKI therapy [7, 8].